Published in Clin Exp Metastasis on May 03, 2012
DNA methylation and cancer diagnosis. Int J Mol Sci (2013) 1.18
Emerging therapeutic biomarkers in endometrial cancer. Biomed Res Int (2013) 0.93
Expression of the mismatch repair gene hMLH1 is enhanced in non-small cell lung cancer with EGFR mutations. PLoS One (2013) 0.76
Genome-wide DNA methylation sequencing reveals miR-663a is a novel epimutation candidate in CIMP-high endometrial cancer. Int J Oncol (2017) 0.75
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A (1998) 9.66
Epigenetics in cancer. Carcinogenesis (2009) 7.49
Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet (2009) 6.98
Two pathogenetic types of endometrial carcinoma. Gynecol Oncol (1983) 6.26
CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene (2002) 5.96
Endometrial cancer. Lancet (2005) 5.50
DNA methylation and cancer. Adv Genet (2010) 3.50
Endometrial carcinoma. N Engl J Med (1996) 3.31
Genomic instability in repeated sequences is an early somatic event in colorectal tumorigenesis that persists after transformation. Nat Genet (1994) 2.95
Microsatellite instability: marker of a mutator phenotype in cancer. Cancer Res (1994) 2.89
Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res (1999) 2.54
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
DNA methylation markers in colorectal cancer. Cancer Metastasis Rev (2010) 2.40
Endometrial cancer. Obstet Gynecol (2008) 2.32
DNA methylation and gene silencing in cancer: which is the guilty party? Oncogene (2002) 2.23
Hypermethylation of the hMLH1 gene promoter in human gastric cancers with microsatellite instability. Cancer Res (1999) 2.09
MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene (1998) 1.99
DNA methylation and cancer. Oncogene (2002) 1.98
Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res (2003) 1.92
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type. J Clin Oncol (2007) 1.87
Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch (2004) 1.80
hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res (1999) 1.70
MLH1 promoter methylation and gene silencing is the primary cause of microsatellite instability in sporadic endometrial cancers. Hum Mol Genet (1999) 1.61
hMLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol (1999) 1.47
Epigenetic lesions causing genetic lesions in human cancer: promoter hypermethylation of DNA repair genes. Eur J Cancer (2000) 1.38
Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer (2006) 1.34
Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer (2002) 1.32
Microsatellite instability and mismatch repair defects in cancer. Mutat Res (1996) 1.25
Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br J Cancer (2009) 1.19
Clinicopathologic significance of defective DNA mismatch repair in endometrial carcinoma. J Clin Oncol (2006) 1.18
Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene (2001) 1.17
Causes and consequences of microsatellite instability in endometrial carcinoma. Cancer Res (1999) 1.16
High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer (2002) 1.15
Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res (1995) 1.14
Role of GPR30 in the mechanisms of tamoxifen resistance in breast cancer MCF-7 cells. Breast Cancer Res Treat (2009) 1.13
Clinical significance of microsatellite instability in endometrial carcinoma. Cancer (2000) 1.07
Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol (1996) 1.06
Chemotherapeutic implications in microsatellite unstable colorectal cancer. Cancer Biomark (2006) 1.01
Frequent hypermethylation of MLH1 promoter in normal endometrium of patients with endometrial cancers. Oncogene (2003) 0.99
Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res (2000) 0.97
Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer. Oncol Rep (2006) 0.96
Favorable survival associated with microsatellite instability in endometrioid endometrial cancers. Obstet Gynecol (2001) 0.96
Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma. Int J Cancer (2006) 0.95
The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res (2006) 0.93
P16 alterations increase the metastatic potential of endometrial carcinoma. Gynecol Oncol (2008) 0.92
Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol (2007) 0.92
High-resolution methylation analysis of the hMLH1 promoter in sporadic endometrial and colorectal carcinomas. Cancer (2003) 0.89
Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol (2002) 0.89
Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability. Int J Oncol (2000) 0.89
Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization. Cancer Biol Ther (2011) 0.87
APC promoter hypermethylation is an early event in endometrial tumorigenesis. Cancer Sci (2009) 0.86
Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions. Eur J Gynaecol Oncol (2009) 0.86
Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review). Oncol Rep (2009) 0.85
Unfavorable prognostic factors associated with high frequency of microsatellite instability and comparative genomic hybridization analysis in endometrial cancer. Clin Cancer Res (2003) 0.84
hMLH1 promoter methylation and silencing in primary endometrial cancers are associated with specific alterations in MBDs occupancy and histone modifications. Gynecol Oncol (2006) 0.83
Analysis of candidate target genes for mononucleotide repeat mutation in microsatellite instability-high (MSI-H) endometrial cancer. Int J Oncol (2009) 0.82
p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas. J Cancer Res Clin Oncol (2003) 0.79
P53/MDM2 overexpression in metastatic endometrial cancer: correlation with clinicopathological features and patient outcome. Clin Exp Metastasis (2007) 0.78
Endometrial cancer in elderly women: A histologic and steroid receptor study. Gerontology (2000) 0.77
Defective mismatch repair and the development of recurrent endometrial carcinoma. Gynecol Oncol (2004) 0.76
Prevalence of allelic loss at TP53 in endometrial carcinomas. Oncology (2010) 0.75
Allelic loss at TP53 in metastatic human endometrial carcinomas. Clin Exp Metastasis (2009) 0.75
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med (1998) 6.09
Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst (1996) 2.51
In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study. Ann Oncol (2005) 1.89
Cathepsin K--a marker of macrophage differentiation? J Pathol (2001) 1.77
First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur J Cancer (2010) 1.57
Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol Res Pract (2008) 1.57
Detection of tumor cells in bone marrow of patients with primary breast cancer: a prognostic factor for distant metastasis. J Clin Oncol (1992) 1.32
Abdominopelvic perivascular epithelioid cell sarcoma (malignant PEComa) mimicking gastrointestinal stromal tumour of the rectum. Histopathology (2005) 1.24
Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study. Ann Oncol (2007) 1.22
Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut (2004) 1.22
Musculoskeletal neoplasms: static and dynamic Gd-DTPA--enhanced MR imaging. Radiology (1989) 1.15
Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. Br J Cancer (2013) 1.14
Intestinal metaplasia at the gastro-oesophageal junction: Helicobacter pylori gastritis or gastro-oesophageal reflux disease? Gut (1998) 1.14
Bone tumors of the hand. A review of 300 cases documented in the Westphalian Bone Tumor Register. Arch Orthop Trauma Surg (1987) 1.12
Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations. Mod Pathol (2000) 1.11
Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice. Br J Cancer (2013) 1.10
Cholangiocarcinoma occurring in a liver with multiple bile duct hamartomas (von Meyenburg complexes). Arch Pathol Lab Med (2000) 1.10
Development of osteoarthritis in the knee joints of Wistar rats after strenuous running exercise in a running wheel by intracranial self-stimulation. Pathol Res Pract (1998) 1.09
Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature. Pathol Res Pract (2001) 1.07
Synthesis, chemical and pharmacological properties of some N-aminoalkyl derivatives of 3,4-pyridinedicarboxamides. Farmaco (1995) 1.06
Correlation between hormone dependency and the regulation of epidermal growth factor receptor by tumor promoters in human mammary carcinoma cells. Proc Natl Acad Sci U S A (1986) 1.05
Closure of osteochondral lesions using chondral fragments and fibrin adhesive. Arch Orthop Trauma Surg (1983) 1.05
hIan5: the human ortholog to the rat Ian4/Iddm1/lyp is a new member of the Ian family that is overexpressed in B-cell lymphoid malignancies. Genes Immun (2004) 1.04
Proteolysis of AA amyloid fibril proteins by matrix metalloproteinases-1, -2, and -3. Am J Pathol (2001) 1.03
Overexpression of platelet-derived growth factor (PDGF) B chain and type beta PDGF receptor in human chronic pancreatitis. Dig Dis Sci (1998) 1.02
Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res (1998) 1.00
Proteolysis of serum amyloid A and AA amyloid proteins by cysteine proteases: cathepsin B generates AA amyloid proteins and cathepsin L may prevent their formation. Ann Rheum Dis (2005) 1.00
Prevalence and pattern of Helicobacter pylori gastritis in the gastric cardia. Am J Gastroenterol (1997) 1.00
Histological findings of tendon-bone healing following anterior cruciate ligament reconstruction with hamstring grafts. Arch Orthop Trauma Surg (2003) 0.99
Differential pattern of DNA-aneuploidy in human malignancies. Pathol Res Pract (1985) 0.99
Clinicopathologic implications of MDM2, p53 and K-ras gene alterations in osteosarcomas: MDM2 amplification and p53 mutations found in progressive tumors. Pathol Res Pract (1998) 0.99
Inflammation and Barrett's carcinogenesis. Pathol Res Pract (2012) 0.98
Short- and mid-term effects of irreversible electroporation on normal renal tissue: an animal model. Cardiovasc Intervent Radiol (2012) 0.98
Benign fibrous histiocytoma of bone. Light- and electron-microscopic observations. J Cancer Res Clin Oncol (1981) 0.98
Chondroblastoma of bone. A clinical, radiological, light and immunohistochemical study. Virchows Arch A Pathol Anat Histopathol (1992) 0.97
Loss of heteroplasmy in the displacement loop of brain mitochondrial DNA in astrocytic tumors. Genes Chromosomes Cancer (1999) 0.97
MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas. J Cancer Res Clin Oncol (1998) 0.96
Immunocytochemical analysis of Ewing's tumors. Patterns of expression of intermediate filaments and desmosomal proteins indicate cell type heterogeneity and pluripotential differentiation. Am J Pathol (1987) 0.96
Hypothalamic osteolipoma: a case report. Gen Diagn Pathol (1997) 0.96
Treatment of postoperative chylothorax by fibrin glue application under thoracoscopic view with use of local anesthesia. J Thorac Cardiovasc Surg (1992) 0.96
Interaction of psychosocial and physical risk factors in the causation of mammary cancer, and its prevention through psychological methods of treatment. J Clin Psychol (2000) 0.95
Spontaneous malignant transformation of conventional giant cell tumor. Skeletal Radiol (2004) 0.95
Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J Cell Mol Med (2008) 0.95
Maximized reduction of primary breast tumor size using preoperative chemotherapy with doxorubicin and docetaxel. J Clin Oncol (1999) 0.94
Helical computerized tomography arteriography for evaluation of live renal donors undergoing laparoscopic nephrectomy. J Urol (1999) 0.94
Homologous genes for X-linked chondrodysplasia punctata in man and mouse. Hum Genet (1983) 0.94
Expression of metallothionein II in intestinal metaplasia, dysplasia, and gastric cancer. Cancer Res (2000) 0.93
The cytogenesis of macrophages and osteoclast-like giant cells in bone tumors with special emphasis on the so-called fibrohistiocytic tumors. Curr Top Pathol (1989) 0.93
Plasmacytoma of the tonsil with AL amyloidosis: evidence of post-fibrillogenic proteolysis of the fibril protein. Virchows Arch (2000) 0.93
Expression of the adhesion molecules ICAM, VCAM, and ELAM in the arteriosclerotic plaque. Gen Diagn Pathol (1996) 0.92
Retroperitoneal schwannoma presenting as an adrenal tumor. Exp Clin Endocrinol Diabetes (2000) 0.92
Expression of thrombospondin-1 in pancreatic carcinoma: correlation with microvessel density. Virchows Arch (2001) 0.92
Histo-diagnostic remarks on bone tumors, a review of 3026 cases registered in "Knochengeschwulstregister Westfalen". Pathol Res Pract (1979) 0.92
Rapid detection of loss of heterozygosity of chromosome 17p by polymerase chain reaction-based variable number of tandem repeat analysis and detection of single-strand conformation polymorphism of intragenic p53 polymorphisms. Virchows Arch (1994) 0.92
Distribution pattern of matrix metalloproteinases 1, 2, 3, and 9, tissue inhibitors of matrix metalloproteinases 1 and 2, and alpha 2-macroglobulin in cases of generalized AA- and AL amyloidosis. Virchows Arch (2000) 0.91
Inducible nitric oxide synthase expression in human urinary bladder cancer. Virchows Arch (2000) 0.91
Chondromyxoid fibroma of the sternum. Case report. Arch Orthop Trauma Surg (1993) 0.91
Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res (1999) 0.91
Canalicular immunostaining of neprilysin (CD10) as a diagnostic marker for hepatocellular carcinomas. Am J Surg Pathol (2001) 0.90
A putative role for cathepsin K in degradation of AA and AL amyloidosis. Am J Pathol (2001) 0.90
Epithelial-myoepithelial carcinoma of the salivary gland--a low grade malignant neoplasm? Report of two cases and review of the literature. Pathol Res Pract (1999) 0.90
Canalicular immunostaining of aminopeptidase N (CD13) as a diagnostic marker for hepatocellular carcinoma. J Clin Pathol (2005) 0.90
Improved grading of bone tumors with the monoclonal antibody Ki-67. J Cancer Res Clin Oncol (1986) 0.89
Genetic and epigenetic alterations in tumor progression in a dedifferentiated chondrosarcoma. Pathol Res Pract (2003) 0.89
p53 gene mutations in osteosarcomas of low-grade malignancy. Hum Pathol (1998) 0.88
"Solid" variant of aneurysmal bone cyst. Pathol Res Pract (1992) 0.88
Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Ther (2001) 0.88
Microphotometric quantitation of enzyme activities in giant cell tumor of bone. A case study. Pathol Res Pract (1985) 0.88
An evaluation of antigen retrieval procedures for immunoelectron microscopic classification of amyloid deposits. J Histochem Cytochem (1999) 0.88
Expression of cathepsin K in the human embryo and fetus. Dev Dyn (1999) 0.88
Genetic Diversity in Populations of Xanthomonas campestris pv. campestris in Cruciferous Weeds in Central Coastal California. Phytopathology (2007) 0.87
Prognostic significance of p53 gene mutations and p53 protein expression in synovial sarcomas. Virchows Arch (1999) 0.87
Possible contribution of aminopeptidase N (APN/CD13) to invasive potential enhanced by interleukin-6 and soluble interleukin-6 receptor in human osteosarcoma cell lines. Clin Exp Metastasis (1999) 0.87
Mesenchymal-epithelial interactions and transforming growth factor-beta expression during mouse prostate morphogenesis. Endocrinology (1994) 0.87
P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J Neurooncol (2012) 0.87
Biologic characterization of human bone tumors. III. Giant cell tumor of bone. A combined electron microscopical, histochemical, and autoradiographical study. Pathol Res Pract (1984) 0.87
Immunohistochemical analysis of several proteolytic enzymes as parameters of cartilage degradation. Pathol Res Pract (1998) 0.87
Two-stage therapy in the treatment of sacral tumors. Arch Orthop Trauma Surg (1989) 0.86
Parosteal osteosarcoma. 2-23-year follow-up of 33 patients. Acta Orthop Scand (1991) 0.86
Rosai-Dorfman disease and generalized AA amyloidosis: a case report. Hum Pathol (2000) 0.86
Alveolar soft part sarcoma of the uterine corpus. Report of two cases and review of the literature. Pathol Res Pract (1998) 0.86
Expression of matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) induced by tumour necrosis factor alpha correlates with metastatic ability in a human osteosarcoma cell line. Virchows Arch (1994) 0.86
Induction of TFF1 gene expression in pancreas overexpressing transforming growth factor alpha. Gut (1999) 0.86
Adamantinoma of long bones. A histopathological and immunohistochemical study of 23 cases. Pathol Res Pract (1995) 0.86
Tumor cell types in osteosarcoma as revealed by electron microscopy. Implications for histogenesis and subclassification. Virchows Arch B Cell Pathol Incl Mol Pathol (1981) 0.85
Protein kinase C desensitization by phorbol esters and its impact on growth of human breast cancer cells. Biochem Biophys Res Commun (1986) 0.85
On telomere shortening in soft-tissue tumors. J Cancer Res Clin Oncol (1998) 0.84
Large-needle biopsy versus thin-needle biopsy in diagnostic pathology of liver diseases. Liver (2001) 0.84
Intermediate-sized filaments in cells of normal human colon mucosa, adenomas and carcinomas. Pathol Res Pract (1982) 0.84
[Evidence-based recommendations on primary treatment of carcinomas of the breast]. Zentralbl Gynakol (2002) 0.84